
TRVI
Healthcare · Biotechnology · $1.95B market cap
$13.65+0.03 (+0.2%)Nov 13, 4:26 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -3.1% over 90 days · 30-day revisions 1 up, 2 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 16, 2027 · upcoming | After the close | -0.14 | — | — |
| Nov 9, 2026 | After the close | -0.13 | -0.13 | 0.0% |
| Aug 6, 2026 | After the close | -0.11 | -0.11 | 0.0% |
| May 5, 2026 | After the close | -0.07 | -0.09 | -28.6% |
| Mar 25, 2026 | Time not confirmed | -0.10 | -0.06 | +39.1% |
| Nov 13, 2025 | After the close | -0.10 | -0.08 | +20.0% |
| Aug 7, 2025 | After the close | -0.10 | -0.09 | +10.0% |
| May 8, 2025 | After the close | -0.12 | -0.09 | +25.0% |
| Mar 18, 2025 | Before the open | -0.12 | -0.11 | +6.1% |
| Nov 6, 2024 | After the close | -0.11 | -0.13 | -18.2% |
| Aug 8, 2024 | After the close | -0.11 | -0.12 | -9.1% |
| May 7, 2024 | After the close | -0.09 | -0.11 | -22.2% |
| Mar 20, 2024 | After the close | -0.09 | -0.08 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with…
| +11.1% |
| Nov 9, 2023 | After the close | -0.09 | -0.08 | +11.1% |
| Aug 10, 2023 | After the close | -0.09 | -0.07 | +22.2% |
| May 11, 2023 | After the close | -0.07 | -0.06 | +14.3% |
| Mar 16, 2023 | After the close | -0.10 | -0.06 | +40.0% |
| Nov 10, 2022 | After the close | -0.13 | -0.12 | +7.7% |
| Aug 11, 2022 | After the close | -0.18 | -0.14 | +22.2% |
| May 12, 2022 | After the close | -0.29 | -0.24 | +17.2% |
| Mar 17, 2022 | After the close | -0.30 | -0.28 | +6.7% |
| Nov 10, 2021 | After the close | -0.39 | -0.34 | +12.8% |
| Aug 12, 2021 | After the close | -0.46 | -0.49 | -6.5% |
| May 13, 2021 | After the close | -0.52 | -0.43 | +17.3% |
| Mar 25, 2021 | After the close | -0.44 | -0.51 | -15.9% |
| Nov 12, 2020 | Before the open | -0.51 | -0.41 | +19.6% |
| Aug 13, 2020 | After the close | -0.48 | -0.41 | +14.6% |
| May 7, 2020 | After the close | -0.44 | -0.48 | -9.1% |
| Mar 16, 2020 | Before the open | -0.51 | -0.37 | +27.5% |
| Nov 14, 2019 | After the close | -0.47 | -0.41 | +12.8% |
| Aug 12, 2019 | After the close | -0.41 | -0.41 | 0.0% |
| Jun 13, 2019 | After the close | -0.52 | -13.85 | -2563.5% |
| Feb 27, 2019 | Time not confirmed | — | 0.00 | — |
| Dec 21, 2018 | Time not confirmed | — | -0.59 | — |